FAK expression (analyzed ex vivo by flow cytometry) has been revealed to be, together with the expression of CXCR4 (CXC chemokine receptor type 4) and integrin VLA-4 (very late antigen-4), an important negative prognosticator of the clinical outcome of AML (33). The gene discussed is PTK2; the disease is acute myeloid leukemia.